Solriamfetol + Placebo
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Binge Eating Disorder
Conditions
Binge Eating Disorder
Trial Timeline
Jun 15, 2021 → Dec 30, 2024
NCT ID
NCT04602936About Solriamfetol + Placebo
Solriamfetol + Placebo is a approved stage product being developed by Jazz Pharmaceuticals for Binge Eating Disorder. The current trial status is unknown. This product is registered under clinical trial identifier NCT04602936. Target conditions include Binge Eating Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04602936 | Approved | UNKNOWN |
Competing Products
11 competing products in Binge Eating Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Zonegran + sugar pill | Eisai | Phase 3 | 77 |
| Dasotraline + Placebo | Sumitomo Pharma | Phase 2/3 | 65 |
| dasotraline 4mg + dasotraline 6mg + Placebo | Sumitomo Pharma | Phase 3 | 77 |
| Dasotraline | Sumitomo Pharma | Phase 3 | 77 |
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo | Novo Nordisk | Phase 3 | 76 |
| Sodium Oxybate | Jazz Pharmaceuticals | Phase 2/3 | 62 |
| Solriamfetol 75mg, 150 mg, or 300 mg | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| RDC-0313 (ALKS 33) + Placebo | Alkermes | Phase 2 | 49 |
| ACT-539313 + Placebo | Idorsia | Phase 2 | 47 |